Menopausal and bone risk assessments in postmenopausal women

Clinical Reviews in Bone and Mineral Metabolism

Volumn 3, Issue 2, 2005, Pages 115-123

  Sikon, Andrea L ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Hormone therapy; Osteoporosis; Postmenopausal; Risk factors; Screening; Secondary osteoporosis

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; CLIMARAPRO; CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; CYCLOSPORIN; ERGOCALCIFEROL; ESCLIM; ESTRADIOL; ESTRADIOL PLUS NORETHISTERONE ACETATE; ESTROGEN; ETHINYLESTRADIOL; FEMHRT; GESTAGEN; GLUCOCORTICOID; HEPARIN; LETROZOLE; LEUPRORELIN; MEDROXYPROGESTERONE ACETATE; METHOTREXATE; PHENOBARBITAL; PHENOTHIAZINE DERIVATIVE; PHENYTOIN; PREFEST; UNCLASSIFIED DRUG;

BONE DENSITY; BONE MASS; CAUCASIAN; CLIMACTERIUM; CONFERENCE PAPER; DISEASE COURSE; DUAL ENERGY X RAY ABSORPTIOMETRY; FRACTURE; HORMONAL THERAPY; HUMAN; LIFESPAN; MEDICAL ASSESSMENT; MENOPAUSE; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PHYSICAL EXAMINATION; POSTMENOPAUSE; PROBABILITY; RISK ASSESSMENT; RISK FACTOR; VITAMIN D DEFICIENCY;

EID: 23844432279     PISSN: 15348644     EISSN: None     Source Type: Journal    
DOI: 10.1385/BMM:3:2:115     Document Type: Conference Paper

References (50)

1. Bone health and osteoporosis: a report of the surgeon general. Executive summary. 2004 US Department of Health and Human Services 2004 I-VIII.
2. US Dept of Health Education and Welfare. 1966 Public Health Service publication No 1000 (Series 11 No. 19); Age at Menopause. Washington, DC.
3. NOF Disease statistics: fast facts, www.nof.org/osteoporosis/stats.htm. Accessed January 8, 2005.
4. NOF America's bone health: the state of osteoporosis and low bone mass. Available at www.nof.org/advocacy/prevalence. Accessed January 8, 2005.
5. AACE Osteoporosis Guidelines Endo Practice 2003. 9(6):545-564.
6. Melton LJ III, Chrischilles EA, Cooper C, et al. 1992 Perspective: how many women have osteoporosis now? J Bone Miner Res 7:1005-1010.
7. Cooper C, Campion G, Melton LJ III. 1992 Hip fractures in the elderly: a worldwide projection. Osteoporosis Int 2:285-289.
8. Huddleston JM, Whitford KH. 2001 Medical care of elderly patients with hip fractures. Mayo Clin Proc 76:295-298.
9. Cancer Facts and Figures 2002 www.cancer.org/downloads/STT/ CancerFacts&Figures2002TM.pdf. Accessed January 27, 2005.
10. Melton LJIII. 1996 Epidemiology of hip fractures: implications of the exponential increase with age. Bone 18:121S-125S.
11. NIH Consensus Development Conference. Osteoporosis prevention, diagnosis, and therapy. 2001 JAMA 285(6):785-795.
12. Riggs BL, Melton LJ III. 1995. The worldwide problem of osteoporosis: insights afforded by epidemiology. Bone 17(5 Suppl):505S-511S.
13. Kado D, Brownder W, Palermo L, et al. 1999 Vertebral fractures and mortality in older women: a prospective study. Arch Intern Med159:1215-1220.
14. Siris ES, Miller PD, Barrett-Connor E, et al. 2001 Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA 286:2815S-2822S.
15. Genant HK, Cooper C, Poor G, et al. 1999 Interim report and recommendations of the World Health Organization Task-Force for osteoporosis. Osteoporosis Int 10:259-264.
16. 15a. Leib E, Lewiecki EM, Binkley N, et al. 2004 official positions of the International Society for Clinical Densitometry. J Clinic Densitometry 7(1):37-44.
17. Andrade S, Majumdar S, Chan A, et al. 2003 Low frequency of treatment of osteoporosis among postmenopausal women following a fracture. Arch Intern Med 163:2052-2057.
18. www.nof.org/physguide/risk_assessment.htm. Accessed January 8, 2005.
19. Federal Register, Vol. 63, No. 121, June 24, 1998.
20. Miller PD, Bonnick SL, Rosen CJ. 1996 Consensus of an international panel on the clinical utility of bone mass measurements in the detection of low bone mass in the adult population. Calcif Tissue Int 58:207-214.
21. Marshall D, Johnell, O. Wedel H. 1996 Meta analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312:1254-1259.
22. Cummings SR, Black D. 1995 Bone mass measurements and risk of fracture in Caucasian women: a review of findings from prospective studies. Am J Med 98: 24S-28S.
23. Klotzbeucher CM, Ross PD, Landsman PB, et al. 2000 Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 15(4):721-39.
24. International center for alcohol policy-international drinking guidelines www.icap.org/opencms/opencms/system/galleries/download/all_pdfs/ ICAP_Reports_English/report 14.pdf. Accessed January 8, 2005. (Dept of Agriculture and Dept. of Health and Human Services and AHA Dietary Guidelines)
25. Cummings SR, Xu L, Chen X, et al. 1994 Bone mass, rates of osteoporotic fractures, and prevention of fractures: are there differences between China and Western countries? Chin Med Sci J (3):197-200.
26. Fitzpatrick LA. 2002 Secondary causes of osteoporosis. Mayo ClinProc 77:453-468.
27. Caplan GA, Scane AC, Francis RM. 1994 Pathogenesis of vertebral crush fractures in women. J R Soc Med 87:200-202.
28. Tannenbaum C, Clark J, Schwartzman K, et al. 2002 Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women. J Clin Endocrinol Metabol 87:4431-4437.
29. Harper KD, Weber TJ. Secondary osteoporosis. Diagnostic considerations. Endocrinol Metabol Clin N Am 27(2):325-348.
30. Dawson-Hughes B. 2004 Racial/ethnic considerations in making recommendations for vitamin D for adult and elderly men and women. Am J Clin Nutr 80(6 Suppl):1763S-1766S.
31. Lips P, Duong T, Oleksik A, et al. 2001 A global study of vitamin D status and parathyroid function in postmenopausal women with osteoporosis: baseline data from the Multiple Outcomes of Raloxifene Evaluation Clinical Trial. J Clin Endocrinol Metabol 86:1212-1221.
32. Malabanan A, Veronikis IE, Holic MF. 1998 Redefining vitamin D insufficiency. Lancet 351:805, 806.
33. Komulainen MH, Kroger H, Tuppurainen MT, et al. 1998 HRT and vit D in prevention of nonvertebral fractures in postmenopausal women; a 5 year randomized trial. Maturitas 31:45-54.
34. Chapuy MC, Arlot ME, Duboeuf F, et al. 1992 Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med 327:1637-1642.
35. Chapuy MC, Arlot ME, Delmas PD, et al. 1994 Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. BMJ 308:1081,1082.
36. Dawson-Huges B, Harris SS, Krall EA, et al. 1997 Effect of calcium and vitamin D supplementation on bone, density in men and women 65 years of age or older. N Engl J Med 337:670-676.
37. Sikon A. Thacker HL, Deal C, et al. 2004 Secondary osteoporosis - are we recognizing it? Menopause 11(6):676.
38. National Institutes of Health Consensus Development Conference Statement on Celiac Disease. 2004 http://consensus.nih.gov/cons/118/118celiac.htm. Accessed December 23, 2004.
39. Stenson WF, Newberry R, Lorinz R, Baldus C, Civitelli R. 2005 Increased prevalence of celiac disease and need for routine screening among patients with osteoporosis. 165:393-399.
40. Executive summary. 2001 Stages of Reproductive Aging Workshop (STRAW). Menopause 8:402-407.
41. Lindsay R, Gallagher J, Kleerekoper M, et al. 2002 Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. JAMA 287:2668-2676.
42. Cetinkaya MB, Kokcu A, Yanik FF, Basoglu T, Malatyalioglu E, Alper T. 2002 Comparison of the effects of transdermal estrogen, oral estrogen, and oral estrogen-progestogen therapy on bone mineral density in postmenopausal women. J Bone Miner Metabol 20(1):44-48.
43. Ettinger D, Ensrud KE, Wallace R, et al. 2004 Effects of ultra low-dose transdermal estradiol on bone mineral density: a randomized clinic trial. Obstet Gynecol 104:443-451.
44. WHI Rossouw JE, Anderson GL, Prentice RL, et al. 2002 Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288:321-333.
45. Anderson G, Limacher M, Assaf A, et al. 2004 The WHI Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative Randomized Controlled Trial. JAMA 291(14):1701-1712.
46. Mendelsohn ME, Kara RH. 1999 The protective effects of estrogen on the cardiovascular system. N Eng J Med 340:1801-1811.
47. Shumaker S, Legault C, Kuller L, et al. 2004 Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA 291(24):2947-2958.
48. Espeland M, Rapp S, Shumaker S, et al. 2004 Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study. JAMA 291(24):2959-2968.
49. NAMS Consensus Statement. 2004 Abridged Recommendations for Estrogen and Progestogen Use in Peri- and Postmenopausal Women Menopause Management. 13: 12-19.
50. ACOG consensus guidelines. American College of Obstetricians and Gynecologists, Women's Health Care Physicians. 2003 ACOG practice bulletin. Clinical management guidelines for obstetrician-gynecologists. N. 50.